Adam Farmer, PhD, MRCP - United Kingdom
Dr Adam Farmer undertook his medical training at University College London, qualifying with the degrees of MB BS BSc (Hons) in 2001. He became a member of the Royal College of Physicians in 2004. Subsequently, he undertook his specialist training in gastroenterology and general medicine in the West Midlands before moving to the Wingate Institute of Neurogastroenterology, Barts and the Royal London School of Medicine, where he undertook a body of research funded by the Medical Research Council.
During this time, he was awarded the degree of PhD at the University of London entitled “Human Psychophysiological Responses to Pain – The Development of Human Pain Endophenotypes”. This work was recognized by a prestigious prize by the American Neurogastroenterology & Motility Society.
He has authored over 45 published articles, written 8 book chapters and has given lectures both nationally and internationally. His main clinical and academic interests concern all aspects of functional gastrointestinal disorders, the management of chronic abdominal pain and the gastrointestinal sequelae of systemic disorders such as diabetes mellitus.
HYPOTHESIS
We hypothesize that liraglutide will prevent progression of gastrointestinal (GI) dysmotility and improve GI related symptomatology/quality of life in patients with type-1 diabetes mellitus, an effect that can be predicting using baseline autonomic nervous system (ANS) parameters.
RESEARCH QUESTION
Will liraglutide prevent progression of GI dysmotility in type-1 diabetics and therefore improve GI symptoms in type-1 diabetics?
Can this effect be predicted using the pre-treatment measurement of novel ANS parameters leading to targeting/personalization of treatment in the future?
FELLOWSHIP AIMS
Import and implement novel methods from the UK, leading to improvements in the analysis and interpretation of ANS parameters and whole and segmental gut transit time
To strengthen the already existing research collaborations between Wingate Institute at Queen Mary University of London and Mech-Sense Aalborg University Hospital
To disseminate knowledge of novel ANS and GI motility assessments to Danish healthcare providers through presentations at symposia, summer schools, dissertation defenses’, as well as the wider scientific community original papers or reviews
And finally based on the obtained results, to inform the design of future high quality clinical trials